MA54311A - Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie - Google Patents

Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie

Info

Publication number
MA54311A
MA54311A MA054311A MA54311A MA54311A MA 54311 A MA54311 A MA 54311A MA 054311 A MA054311 A MA 054311A MA 54311 A MA54311 A MA 54311A MA 54311 A MA54311 A MA 54311A
Authority
MA
Morocco
Prior art keywords
endocrinotherapy
therapeutic
growth factor
factor receptor
fibroblast growth
Prior art date
Application number
MA054311A
Other languages
English (en)
Inventor
Hiroshi Hirai
Akihiro Miura
Hiroshi Sootome
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA54311A publication Critical patent/MA54311A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054311A 2018-11-26 2019-11-25 Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie MA54311A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018220046 2018-11-26

Publications (1)

Publication Number Publication Date
MA54311A true MA54311A (fr) 2022-03-02

Family

ID=70853714

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054311A MA54311A (fr) 2018-11-26 2019-11-25 Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie

Country Status (8)

Country Link
US (1) US20220023300A1 (fr)
EP (1) EP3888643A4 (fr)
JP (2) JPWO2020110974A1 (fr)
KR (1) KR20210095659A (fr)
AU (2) AU2019387843B2 (fr)
MA (1) MA54311A (fr)
TW (1) TWI791928B (fr)
WO (1) WO2020110974A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20240014585A (ko) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
WO2019181876A1 (fr) 2018-03-19 2019-09-26 大鵬薬品工業株式会社 Composition pharmaceutique comprenant du sulfate d'alkyle de sodium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (fr) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 Composé d'alkynylbenzène 3,5-disubstitué et un sel de celui-ci
EP2809312A1 (fr) * 2012-01-31 2014-12-10 Novartis AG Combinaison d'un inhibiteur de rtk avec un anti- strogène et son utilisation pour traiter le cancer
PT3023100T (pt) 2013-07-18 2019-05-29 Taiho Pharmaceutical Co Ltd Fármaco antitumoral para administração intermitente de inibidor de fgfr
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PL3150599T3 (pl) 2014-05-29 2019-03-29 Taiho Pharmaceutical Co., Ltd. Nowy związek tetrahydropirydopirymidyny lub jego sól
SG11201707384YA (en) * 2015-03-31 2017-10-30 Taiho Pharmaceutical Co Ltd Crystal of 3,5-disubstituted benzene alkynyl compound
US11883404B2 (en) * 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20240014585A (ko) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
WO2019181876A1 (fr) * 2018-03-19 2019-09-26 大鵬薬品工業株式会社 Composition pharmaceutique comprenant du sulfate d'alkyle de sodium

Also Published As

Publication number Publication date
AU2019387843A1 (en) 2021-07-15
JPWO2020110974A1 (ja) 2021-10-07
JP2023060012A (ja) 2023-04-27
AU2023203784A1 (en) 2023-07-13
TWI791928B (zh) 2023-02-11
KR20210095659A (ko) 2021-08-02
US20220023300A1 (en) 2022-01-27
WO2020110974A1 (fr) 2020-06-04
EP3888643A1 (fr) 2021-10-06
EP3888643A4 (fr) 2022-08-24
TW202038962A (zh) 2020-11-01
AU2019387843B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
MA54311A (fr) Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie
IL292810A (en) Therapeutic compounds and methods of use
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
EP3890790A4 (fr) Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn
IL287937A (en) acss2 inhibitors and methods of their use
IL283899A (en) Combinations of hdm2-p53 interaction inhibitors and bcl2 inhibitor and their use in the treatment of cancer
JP1770114S (ja) 靴用ストラップ
IL292860A (en) Allosteric egfr inhibitors and methods of using them
ITUB20153797A1 (it) Procedimento per gestire una pluralita' di convertitori buck dc-dc e corrispondente convertitore buck dc-dc
IL288498A (en) Combination therapy of cell-mediated cytotoxic therapy and an inhibitor of the prosurvival bcl2 family protein
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
GB201915618D0 (en) ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
IL280000A (en) Formulations for reducing tumors and methods of using them
GB2590391B (en) Plumbing fixture and methods of operation
MA50581A (fr) Méthodes de traitement et de thérapie d'entretien contre le cancer de la vessie faisant appel à de la gemcitabine
IL311588A (en) LPXC inhibitors and their uses
IL313653A (en) Immuno-oncology inhibitors of MEK and their therapeutic uses
GB202210731D0 (en) Therapeutic agents
IL288003A (en) Cancer treatment methods using chk1 inhibitors
ZA202104656B (en) Deuterated forms and derivatives of volinanserin
TWI799707B (zh) 一種可聚合化合物及應用
IL307680A (en) Methods for the combined administration of ditetrabenazine and a CYP2D6 inhibitor
MA55621A (fr) Formulation séchée par pulvérisation d'un inhibiteur de pyridazinone trpc5
GB201913312D0 (en) Treatment of hypothyroidism and related conditions